<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

TCL Archive

More Patients Get Screened, Colorectal Death Rates Drop

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

Revlimid Also Demonstrates Response in Mantle Cell

FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response

Overall Cancer Mortality Rates Higher For Men Than Women

New Model For Risk Assessment Includes Alcohol, Exercise, Weight

Researchers Identify Five Genes Associated With Melanoma Risk

Stereotactic Body Radiotherapy Could Improve Overall Survival

CMS Issues Coverage Decision For Provenge in Prostate Cancer

Clinical Trials Approved By NCI CTEP Last Month